Beyond the deal: unlocking sustainable success in pharma M&A – The Pharma Letter

An Expert View from Nick Petschek, EMEA managing director at global change management firm Kotter International.
Mergers and acquisitions (M&A) are set to dominate the pharmaceutical industry in 2025, bringing both challenges and opportunities for pharma businesses looking to grow. This expected wave of activity is driven by a confluence of factors—looming patent cliffs, the need to accelerate innovation, and an evolving regulatory landscape. While the appeal of scale, efficiencies, and market dominance drives many deals, the reality is that financial success often hinges on what happens after the ink dries.
For pharma companies, the stakes of post-M&A integration are uniquely high — not just because of the long timelines for assets to produce value, but because at times the industry overlooks a fundamental priority: putting Hippocratic values first, and balancing shareholder returns with sustained value for patients.
This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Try before you buy
7 day trial access
Become a subscriber
Or £77 per month
Chairman, Sanofi Aventis UK
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
The Pharma Letter
39-43 Putney High Street, Putney
London, SW15 1SP
United Kingdom
Copyright © The Pharma Letter 2024   |   Headless Content Management with Blaze

source
This is a newsfeed from leading technology publications. No additional editorial review has been performed before posting.